5/22
03:45 pm
cccc
We Think C4 Therapeutics (NASDAQ:CCCC) Can Afford To Drive Business Growth [Yahoo! Finance]
Low
Report
We Think C4 Therapeutics (NASDAQ:CCCC) Can Afford To Drive Business Growth [Yahoo! Finance]
5/9
12:11 pm
cccc
C4 Therapeutics, Inc. (NASDAQ: CCCC) had its price target raised by analysts at Wells Fargo & Company from $7.00 to $8.00. They now have an "equal weight" rating on the stock.
Low
Report
C4 Therapeutics, Inc. (NASDAQ: CCCC) had its price target raised by analysts at Wells Fargo & Company from $7.00 to $8.00. They now have an "equal weight" rating on the stock.
5/9
10:11 am
cccc
C4 Therapeutics, Inc. (NASDAQ: CCCC) had its price target raised by analysts at Stifel Nicolaus from $13.00 to $14.00. They now have a "buy" rating on the stock.
Low
Report
C4 Therapeutics, Inc. (NASDAQ: CCCC) had its price target raised by analysts at Stifel Nicolaus from $13.00 to $14.00. They now have a "buy" rating on the stock.
5/8
07:08 am
cccc
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
5/8
07:00 am
cccc
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Medium
Report
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
4/29
04:12 pm
cccc
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
4/29
04:01 pm
cccc
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
4/9
07:00 am
cccc
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
Medium
Report
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
4/8
08:14 am
cccc
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Fina
Low
Report
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Fina
4/8
08:00 am
cccc
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
Low
Report
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
3/28
04:52 am
cccc
Here's Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC) [Yahoo! Finance]
Low
Report
Here's Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC) [Yahoo! Finance]
3/21
11:19 am
cccc
Synovial Sarcoma Treatment Market Size to Reach USD 1,144.84 Mn by 2033 [Yahoo! Finance]
Low
Report
Synovial Sarcoma Treatment Market Size to Reach USD 1,144.84 Mn by 2033 [Yahoo! Finance]
3/5
04:43 pm
cccc
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance]
Medium
Report
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance]
3/5
04:30 pm
cccc
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
Medium
Report
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
3/4
07:17 am
cccc
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins [Yahoo! Finance]
Medium
Report
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins [Yahoo! Finance]
3/4
07:00 am
cccc
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
Medium
Report
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
3/1
04:40 pm
cccc
C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched [Seeking Alpha]
Low
Report
C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched [Seeking Alpha]